Sanofi gets FDA warning letter regarding Uroxatral promotion
The FDA has warned Sanofi-Aventis for promotional materials that the agency says improperly state the risks and other safety information of Uroxatral, a treatment for prostate gland enlargement. "Sanofi-Aventis is currently evaluating the letter and will determine an appropriate next step," a company spokeswoman said.
Reuters | 10/27
This story published in FDLI SmartBrief on 10/28/2009
More from SmartBrief:
Amgen agrees to settle drug-pricing suit in Ill. for $7.2M
Wednesday, July 8, 2009
FDA delays human trials of Geron's embryonic stem cell therapy
Wednesday, August 19, 2009
FDA releases risk-mitigation guidance for pharmaceuticals
Thursday, October 1, 2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|